AbbVie raised its full-year earnings forecast on the strength of Botox sales, which are offsetting the collapse of Humira revenue as biosimilar competition erodes the immunology franchise. The aesthetics division is now a material profit driver for the parent company—a shift that underscores how dependent AbbVie's growth has become on neuromodulator demand.
Business & M&A
AbbVie Lifts Forecast as Botox Sales Help Offset Humira Decline
Allergan Aesthetics revenue growth outpaces pharma headwinds in updated guidance.
1-YEAR MOVE
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Aesthetics revenue growth is now material to AbbVie's earnings beat.
For practice owners, this matters because it signals AbbVie's commitment to defending and expanding Botox market share. When a $300 billion pharma company leans on a single aesthetic product to hit guidance, that product gets investment, rebate support, and aggressive pricing discipline. Allergan Aesthetics has already tightened its Alle loyalty program and is running head-to-head clinical trials against competitors' fillers. Expect continued pressure on per-unit economics and tighter rebate terms as AbbVie protects its franchise.
Source: original report ↗
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.